Lineage Cell Therapeutics, Inc.
LCTX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000876343
No open-market purchases or sales by Lineage Cell Therapeutics, Inc. insiders were filed in the last 90 days; 131 institutions reported holding it in 13F filings for Q2 2026, worth $152.7M in total; no superinvestor holds it.
13F holders, Q1 2022
Institutional positions in Lineage Cell Therapeutics, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 109
- −14 vs. Q4 2021
- Shares held
- 72.9M
- −1.53M (−2.1%) vs. Q4 2021
- Total value
- $112.3M
- −$69.6M (−38.3%) vs. Q4 2021
- New holders
- 11
- 20 more added
- Sold out
- 25
- 39 more reduced
1 institution that held it in Q4 2021 haven't filed for Q1 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LCTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 131 | $152.7M |
| Q1 2026 | 130 | $176.5M |
| Q4 2025 | 123 | $169.8M |
| Q3 2025 | 112 | $148.6M |
| Q2 2025 | 129 | $88.4M |
| Q1 2025 | 127 | $49.7M |
| Q4 2024 | 126 | $53.8M |
| Q3 2024 | 114 | $85.6M |
| Q2 2024 | 113 | $94.2M |
| Q1 2024 | 116 | $138.3M |
| Q4 2023 | 115 | $82.5M |
| Q3 2023 | 104 | $89.1M |
| Q2 2023 | 107 | $106.6M |
| Q1 2023 | 116 | $104.7M |
| Q4 2022 | 106 | $76.2M |
| Q3 2022 | 104 | $73.1M |
| Q2 2022 | 100 | $102.7M |
| Q1 2022 | 109 | $112.3M |
| Q4 2021 | 124 | $182.0M |
| Q3 2021 | 115 | $191.7M |
| Q2 2021 | 115 | $208.5M |
| Q1 2021 | 102 | $141.8M |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Lineage Cell Therapeutics, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| JPMorgan Chase & Co | 1,849,662 | $2.85M | 0.00% | +566,385+44.1% | Added |
| Prescott General Partners LLC | 1,851,851 | $2.85M | 0.13% | 00.0% | Unchanged |
| State Street Corp | 2,105,107 | $3.24M | 0.00% | +30,873+1.5% | Added |
| Geode Capital Management, LLC | 2,275,973 | $3.50M | 0.00% | −54,178−2.3% | Reduced |
| Defender Capital, LLC. | 5,006,185 | $7.98M | 2.78% | +8,315+0.2% | Added |
| Vanguard Group Inc | 5,956,931 | $9.17M | 0.00% | −4,724−0.1% | Reduced |
| BlackRock Inc. | 9,809,123 | $15.1M | 0.00% | −199,387−2.0% | Reduced |
| Broadwood Capital Inc | 34,935,485 | $53.8M | 3.88% | +930,106+2.7% | Added |
| IFP Advisors, Inc | 8 | – | – | +8 | New |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −540,824−100.0% | Sold out |
| Ameriprise Financial Inc | 0 | $0 | 0.00% | −304,989−100.0% | Sold out |
| Value Partners Investments Inc. | 0 | $0 | 0.00% | −150,000−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −135,074−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −66,430−100.0% | Sold out |
| Bailard, Inc. | 0 | $0 | 0.00% | −63,400−100.0% | Sold out |
| MetLife Investment Management | 0 | $0 | 0.00% | −49,379−100.0% | Sold out |
| AQR Capital Management LLC | 0 | $0 | 0.00% | −40,688−100.0% | Sold out |
| Parametric Portfolio Associates LLC | 0 | $0 | 0.00% | −27,975−100.0% | Sold out |
| Patriot Financial Group Insurance Agency, LLC | 0 | $0 | 0.00% | −24,000−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −21,610−100.0% | Sold out |
| Credit Suisse AG | 0 | $0 | 0.00% | −20,900−100.0% | Sold out |
| Metropolitan Life Insurance Co | 0 | $0 | 0.00% | −17,572−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −14,258−100.0% | Sold out |
| Raymond James Financial Services Advisors, Inc. | 0 | $0 | 0.00% | −13,961−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −13,429−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −12,142−100.0% | Sold out |
| Captrust Financial Advisors | 0 | $0 | 0.00% | −678−100.0% | Sold out |
| Chilton Capital Management LLC | 0 | $0 | 0.00% | −400−100.0% | Sold out |
| Bivin & Associates, Inc. | 0 | $0 | 0.00% | −600−100.0% | Sold out |
| Meeder Asset Management Inc | 0 | $0 | 0.00% | −5−100.0% | Sold out |
| CWM, LLC | 0 | $0 | 0.00% | −35−100.0% | Sold out |
| Amplius Wealth Advisors, LLC | 0 | $0 | 0.00% | −29−100.0% | Sold out |
| Comprehensive Financial Consultants Institutional, Inc. | 0 | $0 | 0.00% | −5−100.0% | Sold out |
| CoreCap Advisors, LLC | 0 | $0 | 0.00% | −2−100.0% | Sold out |
| Reilly Financial Advisors, LLC | – | – | – | – | Not filed |